5/9
01:47 pm
alvo
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up [Yahoo! Finance]
Neutral
Report
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up [Yahoo! Finance]
5/2
07:15 am
alvo
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
Low
Report
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
4/30
12:02 pm
alvo
Alvotech to produce Humira biosimilar for Cigna's Quallent [Seeking Alpha]
Low
Report
Alvotech to produce Humira biosimilar for Cigna's Quallent [Seeking Alpha]
4/30
04:04 am
alvo
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) [Yahoo! Finance]
Medium
Report
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) [Yahoo! Finance]
4/30
04:00 am
alvo
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Medium
Report
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
4/25
05:01 pm
alvo
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely [Seeking Alpha]
Medium
Report
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely [Seeking Alpha]
4/25
04:49 pm
alvo
Cigna to offer Humira rivals with $0 copay at specialty pharmacy [Reuters]
Medium
Report
Cigna to offer Humira rivals with $0 copay at specialty pharmacy [Reuters]
4/25
04:35 pm
alvo
Cigna to offer Humira rivals with $0 copay at specialty pharmacy [Yahoo! Finance]
Medium
Report
Cigna to offer Humira rivals with $0 copay at specialty pharmacy [Yahoo! Finance]
4/24
04:17 am
alvo
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) [Yahoo! Finance]
Low
Report
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) [Yahoo! Finance]
4/24
04:00 am
alvo
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
Medium
Report
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
4/19
06:58 am
alvo
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S. [Seeking Alpha]
Low
Report
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S. [Seeking Alpha]
4/19
06:16 am
alvo
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) [Yahoo! Finance]
Low
Report
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) [Yahoo! Finance]
4/19
06:16 am
alvo
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) [Yahoo! Finance]
Low
Report
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) [Yahoo! Finance]
4/19
06:10 am
alvo
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Medium
Report
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
4/16
06:28 pm
alvo
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara [Seeking Alpha]
Medium
Report
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara [Seeking Alpha]
4/16
05:38 pm
alvo
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) [Yahoo! Finance]
Low
Report
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) [Yahoo! Finance]
4/16
05:30 pm
alvo
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Low
Report
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
4/16
06:27 am
alvo
J&J beats first-quarter profit estimates on cancer drugs strength [Yahoo! Finance]
Low
Report
J&J beats first-quarter profit estimates on cancer drugs strength [Yahoo! Finance]
4/16
06:24 am
alvo
J&J beats first-quarter profit estimates on cancer drugs strength [Reuters]
Low
Report
J&J beats first-quarter profit estimates on cancer drugs strength [Reuters]
4/3
07:41 am
alvo
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Medium
Report
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
4/3
07:09 am
alvo
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 [Yahoo! Finance]
Medium
Report
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 [Yahoo! Finance]
3/22
04:52 pm
alvo
Alvotech Announces Increase in Number of Own Shares [Yahoo! Finance]
High
Report
Alvotech Announces Increase in Number of Own Shares [Yahoo! Finance]
3/22
04:15 pm
alvo
Alvotech Announces Increase in Number of Own Shares
High
Report
Alvotech Announces Increase in Number of Own Shares
3/22
10:09 am
alvo
Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long [Yahoo! Finance]
Low
Report
Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long [Yahoo! Finance]
3/22
08:07 am
alvo
Alvotech (NYSE: ALVO) had its price target raised by analysts at Barclays PLC from $17.00 to $20.00. They now have an "overweight" rating on the stock.
Low
Report
Alvotech (NYSE: ALVO) had its price target raised by analysts at Barclays PLC from $17.00 to $20.00. They now have an "overweight" rating on the stock.